Modus Therapeutics Overview
- Year Founded
-
2004
- Status
-
Public
- Employees
-
2
- Stock Symbol
-
MODTX
- Share Price
-
$0.02
- (As of Friday Closing)
Modus Therapeutics General Information
Description
Modus Therapeutics Holding AB is a Swedish biotechnology company developing its patented polysaccharide, sevuparin, as a potential treatment for unmet medical needs. Its research focuses on conditions involving severe systemic inflammation, including sepsis and septic shock, severe malaria, and other related disorders, as well as anemia associated with chronic inflammatory conditions such as kidney disease.
Contact Information
Website
www.modustx.comCorporate Office
- Olof Palmes Gata 29 IV
- 111 22 Stockholm
- Sweden
Corporate Office
- Olof Palmes Gata 29 IV
- 111 22 Stockholm
- Sweden
Modus Therapeutics Timeline
Modus Therapeutics Stock Performance
As of 13-Nov-2026, Modus Therapeutics’s stock price is $0.02. Its current market cap is $2.91M with 169M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.02 | $0.02 | $0.02 - $0.06 | $2.91M | 169M | 1.21M | -$0.02 |
Modus Therapeutics Financials Summary
As of 30-Jun-2026, Modus Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 5,041 | 2,225 | 5,167 | 7,703 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (1,867) | (1,847) | (1,498) | (1,543) |
| Net Income | (1,878) | (1,887) | (1,470) | (1,684) |
| Total Assets | 1,366 | 1,379 | 443 | 2,005 |
| Total Debt | 0 | 0 | 0 | 0 |
Modus Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Modus Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Modus Therapeutics Comparisons
Industry
Financing
Details
Modus Therapeutics Competitors (25)
One of Modus Therapeutics’s 25 competitors is Inovio Pharmaceuticals, a Corporation company based in Plymouth Meeting, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| uniQure | Formerly VC-backed | Amsterdam, Netherlands | ||||
| Xalud Therapeutics | Venture Capital-Backed | New York, NY | ||||
| Galectin Therapeutics | Corporation | Norcross, GA | ||||
| Supernus | Formerly VC-backed | Rockville, MD |
Modus Therapeutics Patents
Modus Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-202314100-D0 | New medical use | Inactive | 15-Sep-2023 | ||
| GB-202302278-D0 | New medical use | Inactive | 17-Feb-2023 | ||
| GB-2627263-A | New medical use | Inactive | 17-Feb-2023 | ||
| EP-4665360-A1 | New medical use of sevuparin in the treatment of endotoxemia | Pending | 17-Feb-2023 | ||
| US-20260232720-A1 | New medical use of sevuparin in the treatment of endotoxemia | Pending | 17-Feb-2023 | A61K31/727 |
Modus Therapeutics Signals
Modus Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Modus Therapeutics ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Modus Therapeutics FAQs
-
When was Modus Therapeutics founded?
Modus Therapeutics was founded in 2004.
-
Where is Modus Therapeutics headquartered?
Modus Therapeutics is headquartered in Stockholm, Sweden.
-
What is the size of Modus Therapeutics?
Modus Therapeutics has 2 total employees.
-
What industry is Modus Therapeutics in?
Modus Therapeutics’s primary industry is Drug Discovery.
-
Is Modus Therapeutics a private or public company?
Modus Therapeutics is a Public company.
-
What is Modus Therapeutics’s stock symbol?
The ticker symbol for Modus Therapeutics is MODTX.
-
What is the current stock price of Modus Therapeutics?
As of 13-Nov-2026 the stock price of Modus Therapeutics is $0.02.
-
What is the current market cap of Modus Therapeutics?
The current market capitalization of Modus Therapeutics is $2.91M.
-
Who are Modus Therapeutics’s competitors?
Inovio Pharmaceuticals, uniQure, Xalud Therapeutics, Galectin Therapeutics, and Supernus are some of the 25 competitors of Modus Therapeutics.
-
What is Modus Therapeutics’s annual earnings per share (EPS)?
Modus Therapeutics’s EPS for 12 months was -$0.02.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process